Balyasny Asset Management
SRPT icon

Balyasny Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Balyasny Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.26M Sell
150,000
-50,300
-25% -$974K ﹤0.01% 1559
2025
Q4 		$4.31M Hold
200,300
– – 0.01% 1474
2025
Q3 		$3.86M Buy
+200,300
New +$3.57M ﹤0.01% 1493
2025
Q2 		– Sell
-30,300
Closed -$1.93M – 3319
2025
Q1 		$1.93M Buy
+30,300
New +$3.19M ﹤0.01% 1718
2024
Q4 		– Sell
-60,000
Closed -$7.49M – 3238
2024
Q3 		$7.49M Sell
60,000
-65,000
-52% -$8.99M 0.01% 1082
2024
Q2 		$19.8M Buy
+125,000
New +$16.1M 0.03% 612
2023
Q4 		– Sell
-61,900
Closed -$7.5M – 2879
2023
Q3 		$7.5M Sell
61,900
-65,000
-51% -$7.35M 0.02% 953
2023
Q2 		$14.5M Buy
126,900
+42,400
+50% +$5.47M 0.03% 640
2023
Q1 		$11.6M Buy
+84,500
New +$11M 0.03% 718
2022
Q3 		– Sell
-92,700
Closed -$6.95M – 3237
2022
Q2 		$6.95M Buy
+92,700
New +$6.82M 0.02% 804
2021
Q4 		– Sell
-78,000
Closed -$7.21M – 2577
2021
Q3 		$7.21M Buy
+78,000
New +$6.01M 0.03% 696
2021
Q2 		– Sell
-221,000
Closed -$16.5M – 2325
2021
Q1 		$16.5M Buy
221,000
+83,500
+61% +$7.71M 0.08% 329
2020
Q4 		$23.4M Buy
+137,500
New +$20.4M 0.13% 214
2019
Q3 		– Sell
-110,000
Closed -$14.3M – 1559
2019
Q2 		$14.3M Buy
110,000
+23,000
+26% +$2.8M 0.09% 305
2019
Q1 		$10.4M Buy
87,000
+59,000
+211% +$7.59M 0.07% 374
2018
Q4 		$3.06M Buy
+28,000
New +$3.5M 0.02% 611
2018
Q3 		– Sell
-113,700
Closed -$15M – 2013
2018
Q2 		$15M Sell
113,700
-71,300
-39% -$6.72M 0.07% 378
2018
Q1 		$13.7M Buy
+185,000
New +$12.3M 0.06% 429
2017
Q1 		– Sell
-300,000
Closed -$8.23M – 1772
2016
Q4 		$8.23M Buy
+300,000
New +$12M 0.04% 539

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management's SRPT Position: Q1 2026 in Review

Balyasny Asset Management increased its Sarepta Therapeutics (SRPT) stake by 328% in Q1 2026, buying an estimated $5.81M and bringing the position to 392,044 shares worth $8.53M. The position accounts for 0.01% of the portfolio, ranked #1107.

Balyasny Asset Management first reported a position in SRPT in Q2 2013 and has held it in 33 quarters since. The position peaked at $84.2M in Q2 2024. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Balyasny Asset Management held 392,044 shares of Sarepta Therapeutics worth $8.53M as of Q1 2026.
  • Balyasny Asset Management bought 300,425 Sarepta Therapeutics shares in Q1 2026, an estimated $5.81M.
  • Sarepta Therapeutics made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1107 holding.
  • Balyasny Asset Management first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 33 quarters since.
  • Balyasny Asset Management's Sarepta Therapeutics position peaked at $84.2M in Q2 2024.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.